Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Jun 24 2025

0mins

UPXI-8.94%

TMDE-11.15%

NINE0%

Should l Buy UPXI?

Source: Benzinga

Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy UPXI?" and start using high-conviction signals backed by rigorous historical data.

UPXI

$0.7435+Infinity%1D

Analyst Views on UPXI

Wall Street analysts forecast UPXI stock price to rise

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.816

Low

6.00

Averages

6.00

High

6.00

Current: 0.816

Low

6.00

Averages

6.00

High

6.00

Cantor Fitzgerald

Brett Knoblauch

Overweight

downgrade

$6 -> $2

2026-02-11

New

Reason

Cantor Fitzgerald

Brett Knoblauch

Price Target

$6 -> $2

AI Analysis

2026-02-11

New

downgrade

Overweight

Reason

Cantor Fitzgerald analyst Brett Knoblauch lowered the firm's price target on Upexi to $2 from $6 and keeps an Overweight rating on the shares following the Q2 results. The firm continues to believe the Solana ecosystem is one of the most "vibrant" ecosystems across crypto, and while recent price performance paints a negative light on Solana, the core thesis that Solana can be the internet of capital markets remains true, the analyst tells investors in a research note.

Cantor Fitzgerald

Overweight -> NULL

downgrade

$16 -> $6

2025-11-14

Reason

Cantor Fitzgerald

Price Target

$16 -> $6

2025-11-14

downgrade

Overweight -> NULL

Reason

Cantor Fitzgerald lowered the firm's price target on Upexi to $6 from $16 and keeps an Overweight rating on the shares. With a large SOL treasury, discounted valuation, and new share repurchase authorization, the setup offers an appealing risk/reward profile, the analyst tells investors in a research note. The firm has removed the value applied to its treasury operations from its model.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for UPXI

Unlock Now

About UPXI

Upexi, Inc. is a solana-focused treasury company. The Company is a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. The Company’s brands include Lucky Tail, PRAX, and Cure Mushrooms. Lucky Tail is a pet care product brand that provides products from grooming tools to nutritional products. Cure Mushrooms is a full line of medicinal mushroom products, designed by effect for consumers, which offers mushroom extracts in tinctures and gummies. PRAX is a full line of medicinal mushroom products, designed by effect for consumers, which are cultivated, extracted, and produced in the United States. Its products are distributed in the United States of America and internationally through multiple entities and managed through locations in Florida.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

UPEXI Reports Q2 EPS of -$2.94

2 days agomoomoo

Market Overview: The U.S. stock market is experiencing fluctuations, with the S&P 500 index showing a slight decline of 2.94 points.
Economic Indicators: Recent economic data suggests mixed signals, impacting investor sentiment and market performance.
Sector Performance: Various sectors are reacting differently to economic news, with some showing resilience while others struggle.
Future Outlook: Analysts are closely monitoring upcoming economic reports that could influence market trends and investor decisions.

UPEXI Reports Q2 Revenue of $8.1 Million

2 days agomoomoo

Company Overview: UPEXIQ reported a revenue of USD 8.1 million for the second quarter.
Financial Performance: The revenue reflects the company's growth and operational success during this period.
Market Position: UPEXIQ continues to strengthen its position in the market with increasing financial results.
Future Outlook: The company is optimistic about future performance and potential growth opportunities.

UPEXI Reports Q2 Net Loss of USD 178.9 Million

2 days agomoomoo

Financial Performance: UPEX reported a net income of USD 178.9 million for the second quarter.
Comparison to Previous Period: This figure reflects a significant change compared to previous financial results, indicating growth or decline in profitability.

UPEXI ANNOUNCES FINANCIAL RESULTS FOR FISCAL SECOND QUARTER 2026

2 days agomoomoo

Financial Performance: UPEXIRE reported its fiscal results for the second quarter of 2026, showcasing key financial metrics and performance indicators.
Revenue Trends: The report highlights trends in revenue generation, including growth areas and any declines in specific sectors.
Operational Insights: UPEXIRE provides insights into operational efficiencies and challenges faced during the quarter, impacting overall performance.
Future Outlook: The company outlines its strategic plans and expectations for the upcoming quarters, addressing market conditions and potential opportunities.

UPEXI Reports Q2 Gross Profit of $6.7 Million

2 days agomoomoo

Company Overview: UPEXIQ reported a gross profit of $6.7 million for the second quarter.
Financial Performance: The financial results indicate a strong performance in the company's operations during this period.

Upexi (UPXI) Q2 2026 Earnings Call Transcript

2 days agoNASDAQ.COM

UPEXI Reports Q2 EPS of -$2.94

2 days agomoomoo

Market Overview: The U.S. stock market is experiencing fluctuations, with the S&P 500 index showing a slight decline of 2.94 points.
Economic Indicators: Recent economic data suggests mixed signals, impacting investor sentiment and market performance.
Sector Performance: Various sectors are reacting differently to economic news, with some showing resilience while others struggle.
Future Outlook: Analysts are closely monitoring upcoming economic reports that could influence market trends and investor decisions.

UPEXI Reports Q2 Revenue of $8.1 Million

2 days agomoomoo

Company Overview: UPEXIQ reported a revenue of USD 8.1 million for the second quarter.
Financial Performance: The revenue reflects the company's growth and operational success during this period.
Market Position: UPEXIQ continues to strengthen its position in the market with increasing financial results.
Future Outlook: The company is optimistic about future performance and potential growth opportunities.

UPEXI Reports Q2 Net Loss of USD 178.9 Million

2 days agomoomoo

Financial Performance: UPEX reported a net income of USD 178.9 million for the second quarter.
Comparison to Previous Period: This figure reflects a significant change compared to previous financial results, indicating growth or decline in profitability.

UPEXI ANNOUNCES FINANCIAL RESULTS FOR FISCAL SECOND QUARTER 2026

2 days agomoomoo

Financial Performance: UPEXIRE reported its fiscal results for the second quarter of 2026, showcasing key financial metrics and performance indicators.
Revenue Trends: The report highlights trends in revenue generation, including growth areas and any declines in specific sectors.
Operational Insights: UPEXIRE provides insights into operational efficiencies and challenges faced during the quarter, impacting overall performance.
Future Outlook: The company outlines its strategic plans and expectations for the upcoming quarters, addressing market conditions and potential opportunities.

UPEXI Reports Q2 Gross Profit of $6.7 Million

2 days agomoomoo

Company Overview: UPEXIQ reported a gross profit of $6.7 million for the second quarter.
Financial Performance: The financial results indicate a strong performance in the company's operations during this period.